TYK2 Inhibitor FDA Approved for Psoriasis BMS made a mega bet on deucravacitinib, an in-house experimental TYK2 drug, in the leadup to the big Celgene buyout, keeping it while auctioning off Celgene’s top-selling Otezla to Amgen for $13.4 billion https://t.co/wPN62jBIvL https://t.co/Cj6svOoiaJ